Biotech firm Galapagos to wind down cell therapy business

Core Viewpoint - Biotechnology firm Galapagos will cease its cell therapy business after unsuccessful attempts to sell it, resulting in the loss of 365 jobs across Europe, China, and the U.S. [1] Company Summary - Galapagos is winding down its cell therapy operations due to failed sale efforts [1] - The decision will impact 365 employees in multiple regions, including Europe, China, and the U.S. [1] Industry Summary - The biotechnology sector is facing challenges, as evidenced by Galapagos' decision to exit a segment of its business [1]